Yöntem Yaman
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Yöntem Yaman has a total of 80 co-authors. Here are the top co-authors by number of shared publications:
- Kursat Ozdilli
Department of Medical Biology, Faculty of Medicine, Istanbul Medipol University, Istanbul 34810, Turkey
6 shared publications - Nihan Bayram
Pediatric Hematology and Oncology
6 shared publications - Murat Elli
Department of Pediatric Hematology and Oncology, İstanbul Medipol University, İstanbul, Turkey
5 shared publications - Sema Anak
Pediatric Bone Marrow Transplantation Unit, Istanbul Medipol University, Bagcilar, Istanbul, Turkey
5 shared publications - Serdar Nepesov
Department of Pediatric Immunology and Allergy, School of Medicine, Istanbul University-Cerrahpaşa, Fatih Istanbul, Türkiye
5 shared publications Yeşim Oymak
Department of Paediatric Haematology, Dr. Behçet Uz Children’s Hospital, İzmir, Turkey
3 shared publications
Latest Publications
- Open Access
- 25 September 2026
- Published by Springer Nature in Annals of Hematology
Real-world outcomes of children with first relapsed acute lymphoblastic leukemia treated according to the ALL-IC REL 2016 guideline in Türkiye
- 25 September 2026
- Published by Springer Nature in Annals of Hematology
Open AccessReal-world outcomes of children with first relapsed acute lymphoblastic leukemia treated according to the ALL-IC REL 2016 guideline in Türkiye
- Open Access
- 3 December 2025
- Published by Springer Nature in Molecular and Cellular Pediatrics
- Vol. 12 (1) , 25
Pazopanib as maintenance therapy in pediatric ewing sarcoma: a case series of six patients
Introduction: Ewing sarcoma (ES) is an aggressive pediatric bone and soft tissue malignancy. Despite advances in multimodal therapy, outcomes remain suboptimal for patients with high-risk features such as large tumor volume, poor histologic response, disseminated disease, or relapse. Maintenance strategies have gained interest in pediatric sarcomas, but evidence in ES is limited. Pazopanib, an oral multi-targeted tyrosine kinase inhibitor, has shown activity in adult soft tissue sarcomas; however, data on its use as maintenance therapy in pediatric ES are scarce. Methods: We retrospectively analyzed six pediatric ES patients who received pazopanib as maintenance therapy following consolidation treatment or, when applicable, after high-dose chemotherapy with autologous stem cell transplantation. Indications included poor-risk localized disease, relapse, or stable residual disease after frontline therapy. Pazopanib dosing, duration, toxicity, and clinical outcomes were reviewed. Results: Pazopanib was administered at doses of 400–800 mg in five patients and 200 mg twice daily in one patient. Hair depigmentation occurred in all patients, and one patient developed reversible hepatotoxicity requiring temporary interruption and dose reduction. At a median follow-up of 47 months (range, 18–53 months), five patients remained in complete remission. One patient with disseminated disease at diagnosis developed intracranial relapse 18 months post-transplant while still receiving pazopanib. Conclusions: In this retrospective cohort, pazopanib was generally well tolerated and may have a potential role as maintenance therapy in selected high-risk pediatric ES patients. However, efficacy cannot be determined from this limited series, and prospective studies are needed to better define its clinical utility in ES.
- 3 December 2025
- Published by Springer Nature in Molecular and Cellular Pediatrics
- Vol. 12 (1) , 25
Open AccessPazopanib as maintenance therapy in pediatric ewing sarcoma: a case series of six patients
Introduction: Ewing sarcoma (ES) is an aggressive pediatric bone and soft tissue malignancy. Despite advances in multimodal therapy, outcomes remain suboptimal for patients with high-risk features such as large tumor volume, poor histologic response, disseminated disease, or relapse. Maintenance strategies have gained interest in pediatric sarcomas, but evidence in ES is limited. Pazopanib, an oral multi-targeted tyrosine kinase inhibitor, has shown activity in adult soft tissue sarcomas; however, data on its use as maintenance therapy in pediatric ES are scarce. Methods: We retrospectively analyzed six pediatric ES patients who received pazopanib as maintenance therapy following consolidation treatment or, when applicable, after high-dose chemotherapy with autologous stem cell transplantation. Indications included poor-risk localized disease, relapse, or stable residual disease after frontline therapy. Pazopanib dosing, duration, toxicity, and clinical outcomes were reviewed. Results: Pazopanib was administered at doses of 400–800 mg in five patients and 200 mg twice daily in one patient. Hair depigmentation occurred in all patients, and one patient developed reversible hepatotoxicity requiring temporary interruption and dose reduction. At a median follow-up of 47 months (range, 18–53 months), five patients remained in complete remission. One patient with disseminated disease at diagnosis developed intracranial relapse 18 months post-transplant while still receiving pazopanib. Conclusions: In this retrospective cohort, pazopanib was generally well tolerated and may have a potential role as maintenance therapy in selected high-risk pediatric ES patients. However, efficacy cannot be determined from this limited series, and prospective studies are needed to better define its clinical utility in ES.
- 11 November 2024
- Published by Wolters Kluwer Health in Journal of Pediatric Hematology/Oncology
- Vol. 47 (1) , e10-e14
Eltrombopag for Treatment of Thrombocytopenia After Autologous Stem Cell Transplantation in Children: Single Center Experience
Introduction: Thrombocytopenia is a common clinical problem in cancer patients undergoing high-dose chemotherapy and autologous hematopoietic stem cell transplantation (HSCT). It can occur as prolonged isolated thrombocytopenia (PIT) or secondary failure of platelet recovery (SFPR) and may cause potentially fatal bleeding. However, data on the treatment of post-transplant thrombocytopenia is still lacking. Methods: We reported our practices involving 15 pediatric patients who received eltrombopag (ELT) treatment for PIT and SFPR after autologous HSCT. Results: The overall response was 78.5% (11/14), with 1 patient excluded due to noncompliance. The 12 surviving patients' median follow up was 699 days (range: 167 to 2250 d). Conclusions: Our study indicates the efficacy and safety of ELT for treating PIT and SFPR after autologous HSCT in pediatric patients. However, more studies are needed to confirm these findings in children.
- 11 November 2024
- Published by Wolters Kluwer Health in Journal of Pediatric Hematology/Oncology
- Vol. 47 (1) , e10-e14
Eltrombopag for Treatment of Thrombocytopenia After Autologous Stem Cell Transplantation in Children: Single Center Experience
Introduction: Thrombocytopenia is a common clinical problem in cancer patients undergoing high-dose chemotherapy and autologous hematopoietic stem cell transplantation (HSCT). It can occur as prolonged isolated thrombocytopenia (PIT) or secondary failure of platelet recovery (SFPR) and may cause potentially fatal bleeding. However, data on the treatment of post-transplant thrombocytopenia is still lacking. Methods: We reported our practices involving 15 pediatric patients who received eltrombopag (ELT) treatment for PIT and SFPR after autologous HSCT. Results: The overall response was 78.5% (11/14), with 1 patient excluded due to noncompliance. The 12 surviving patients' median follow up was 699 days (range: 167 to 2250 d). Conclusions: Our study indicates the efficacy and safety of ELT for treating PIT and SFPR after autologous HSCT in pediatric patients. However, more studies are needed to confirm these findings in children.
- Open Access
- 1 July 2022
- Published by Caleo in Turkish Archives of Pediatrics
- Vol. 57 (4) , 398-405
Clinical, Genetic, and Outcome Characteristics of Pediatric Patients with Primary Hemophagocytic Lymphohistiocytosis
Objective: In this study, we sought to describe the clinical, laboratory, and genetic character- istics of patients diagnosed with primary hemophagocytic lymphohistiocytosis. Thus, we aimed to evaluate the early diagnosis and appropriate treatment options for pediatric hemophago- cytic lymphohistiocytosis patients. Materials and Methods: Medical records of 9 patients diagnosed with primary hemophago- cytic lymphohistiocytosis between November 2013 and December 2019 were analyzed retro- spectively. Clinical, genetic, and laboratory characteristics, family histories, initial complaints, physical examination findings, age at diagnosis, treatment choices, and clinical follow-up of all patients were investigated. Results: The mean age at diagnosis was 11 months (range: 1.5 months to 17 years). Genetic analysis was performed in all patients, and a disease-related mutation was detected in 8 (89%) of them. Among clinical features, 6 (66%) patients had fever, 5 (56%) had splenomegaly, 4 (44%) had lymphadenopathy, 4 (44%) had skin rash, and 4 (44%) had neurological findings. Hemophagocytosis was observed in the bone marrow samples of 6 (66%) patients. Disease remission was achieved in 7 (78%) patients. Hematopoietic stem cell transplantation was per- formed in 7 (78%) patients. Conclusion: Hemophagocytic lymphohistiocytosis may present with different clinical symptoms that can cause a significant diagnostic delay. The only curative treatment option in primary hemophagocytic lymphohistiocytosis patients is hematopoietic stem cell transplantation. The chemotherapy should be started as early as possible, in order to achieve a disease remission. Patients should be referred to the appropriate bone marrow transplant center for hematopoi- etic stem cell transplantation as soon as they reach the disease remission. Cite this article as: Nepesov S, Yaman Y, Elli M, et al. Clinical, genetic, and outcome characteristics of pediatric patients with primary hemophagocytic lymphohistiocytosis. Turk Arch Pediatr. 2022;57(4):398-405.
- 1 July 2022
- Published by Caleo in Turkish Archives of Pediatrics
- Vol. 57 (4) , 398-405
Open AccessClinical, Genetic, and Outcome Characteristics of Pediatric Patients with Primary Hemophagocytic Lymphohistiocytosis
Objective: In this study, we sought to describe the clinical, laboratory, and genetic character- istics of patients diagnosed with primary hemophagocytic lymphohistiocytosis. Thus, we aimed to evaluate the early diagnosis and appropriate treatment options for pediatric hemophago- cytic lymphohistiocytosis patients. Materials and Methods: Medical records of 9 patients diagnosed with primary hemophago- cytic lymphohistiocytosis between November 2013 and December 2019 were analyzed retro- spectively. Clinical, genetic, and laboratory characteristics, family histories, initial complaints, physical examination findings, age at diagnosis, treatment choices, and clinical follow-up of all patients were investigated. Results: The mean age at diagnosis was 11 months (range: 1.5 months to 17 years). Genetic analysis was performed in all patients, and a disease-related mutation was detected in 8 (89%) of them. Among clinical features, 6 (66%) patients had fever, 5 (56%) had splenomegaly, 4 (44%) had lymphadenopathy, 4 (44%) had skin rash, and 4 (44%) had neurological findings. Hemophagocytosis was observed in the bone marrow samples of 6 (66%) patients. Disease remission was achieved in 7 (78%) patients. Hematopoietic stem cell transplantation was per- formed in 7 (78%) patients. Conclusion: Hemophagocytic lymphohistiocytosis may present with different clinical symptoms that can cause a significant diagnostic delay. The only curative treatment option in primary hemophagocytic lymphohistiocytosis patients is hematopoietic stem cell transplantation. The chemotherapy should be started as early as possible, in order to achieve a disease remission. Patients should be referred to the appropriate bone marrow transplant center for hematopoi- etic stem cell transplantation as soon as they reach the disease remission. Cite this article as: Nepesov S, Yaman Y, Elli M, et al. Clinical, genetic, and outcome characteristics of pediatric patients with primary hemophagocytic lymphohistiocytosis. Turk Arch Pediatr. 2022;57(4):398-405.
- 21 February 2022
- Published by Wiley in Pediatric Transplantation
- Vol. 26 (4) , e14255
HLA ‐ matched related donor hematopoietic stem cell transplantation in a patient with polynucleotide kinase 3–phosphatase mutation developed acute myeloid leukemia
Background: PNPK gene mutations result in DNA repair disorders and have a spectrum of neurodevelopmental manifestations. To date, cancer predisposition has not been described in patients with PNKP mutations.Observation: Here, we report a patient with PNKP mutation, who developed AML at age of five and underwent reduced‐intensity HSCT.Conclusion: Although many DNA repair disorders are known to have increased risk of malignancy, association between PNKP mutations and malignancy is not well‐described. This report is the first description of a PNPK mutation patient developing a malignancy and undergoing curative HSCT.
- 21 February 2022
- Published by Wiley in Pediatric Transplantation
- Vol. 26 (4) , e14255
HLA ‐ matched related donor hematopoietic stem cell transplantation in a patient with polynucleotide kinase 3–phosphatase mutation developed acute myeloid leukemia
Background: PNPK gene mutations result in DNA repair disorders and have a spectrum of neurodevelopmental manifestations. To date, cancer predisposition has not been described in patients with PNKP mutations.Observation: Here, we report a patient with PNKP mutation, who developed AML at age of five and underwent reduced‐intensity HSCT.Conclusion: Although many DNA repair disorders are known to have increased risk of malignancy, association between PNKP mutations and malignancy is not well‐described. This report is the first description of a PNPK mutation patient developing a malignancy and undergoing curative HSCT.
- 16 April 2021
- Published by Wiley in Pediatric Transplantation
- Vol. 25 (4) , e14024
Clinical Efficacy of Ruxolitinib Monotherapy and Haploidentical Hematopoeitic Stem Cell Transplantation in a Child with Philadelphia Chromosome‐like Relapsed/Refractory acute lymphoblastic leukemia
Introduction: (Ph‐like) ALL is a subset of leukemia which has a gene expression profile similar to Ph+disease, but without the presence of BCR‐ABL1 translocation.Case description: We reported an exceptional case of a child with relapsed Ph‐like ALL with IKZF1 gene deletion treated with high‐dose ruxolitinib as monotherapy, after multi‐agent chemotherapy. He remains in continued MRD‐negative leukemia remission with full donor chimerism at 12 months post‐HSCT.Discussion: The circumstance that makes our case featured is the usage of ruxolitinib as monotherapy. This report, we believe, is a pioneering report for a frequent disease with a high risk of failure for the outcome.
- 16 April 2021
- Published by Wiley in Pediatric Transplantation
- Vol. 25 (4) , e14024
Clinical Efficacy of Ruxolitinib Monotherapy and Haploidentical Hematopoeitic Stem Cell Transplantation in a Child with Philadelphia Chromosome‐like Relapsed/Refractory acute lymphoblastic leukemia
Introduction: (Ph‐like) ALL is a subset of leukemia which has a gene expression profile similar to Ph+disease, but without the presence of BCR‐ABL1 translocation.Case description: We reported an exceptional case of a child with relapsed Ph‐like ALL with IKZF1 gene deletion treated with high‐dose ruxolitinib as monotherapy, after multi‐agent chemotherapy. He remains in continued MRD‐negative leukemia remission with full donor chimerism at 12 months post‐HSCT.Discussion: The circumstance that makes our case featured is the usage of ruxolitinib as monotherapy. This report, we believe, is a pioneering report for a frequent disease with a high risk of failure for the outcome.
- 16 January 2021
- Published by Wiley in Pediatric Transplantation
- Vol. 25 (5) , e13962
Eltrombopag for treatment of thrombocytopenia after allogeneic hematopoietic cell transplantation in children: Single‐centre experience
Delayed recovery of thrombocytopenia is a well‐known complication after allogeneic HSCT. Eltrombopag (ELT), a thrombopoietin receptor agonist (TRAs), induces platelet maturation and release. Mostly conducted in adults, some of the previous studies have shown that ELT seems to enhance platelet recovery for post‐allogeneic HSCT thrombocytopenia, appears efficacious, and offers transfusion independence. To evaluate the safety and efficacy of ELT in pediatric patients with prolonged isolated thrombocytopenia (PIT) or secondary failure of platelet recovery (SFPR) after alloHSCT. Retrospective analysis of childhood patients who received treatment with ELT for persistent thrombocytopenia after alloHSCT between May 2016 and August 2019. We evaluated the safety and efficacy of ELT in 18 childhood patients with PIT or SFPR after alloHSCT. Eltrombopag (50 mg/d) treatment was started in all patients, above 6 years of age and 20 kg weight, who had thrombocytopenia despite neutrophil engraftment on the 30th day of HSCT. Our objective was to decrease the need for platelet transfusion and have a platelet count of more than 50 000/µL. The overall response rate was 77.7%. The median time to achieve a platelet level above 30 000/µL and 50 000/µL was 21 and 44 days, respectively. In four patients, platelet count never reached 30 000/mm3. In two patients, the treatment was discontinued due to grade 3 hepatotoxicity. Our study supports the efficacy and relative safety of ELT use for the treatment of PIT and SFPR seen after alloHSCT in children.
- 16 January 2021
- Published by Wiley in Pediatric Transplantation
- Vol. 25 (5) , e13962
Eltrombopag for treatment of thrombocytopenia after allogeneic hematopoietic cell transplantation in children: Single‐centre experience
Delayed recovery of thrombocytopenia is a well‐known complication after allogeneic HSCT. Eltrombopag (ELT), a thrombopoietin receptor agonist (TRAs), induces platelet maturation and release. Mostly conducted in adults, some of the previous studies have shown that ELT seems to enhance platelet recovery for post‐allogeneic HSCT thrombocytopenia, appears efficacious, and offers transfusion independence. To evaluate the safety and efficacy of ELT in pediatric patients with prolonged isolated thrombocytopenia (PIT) or secondary failure of platelet recovery (SFPR) after alloHSCT. Retrospective analysis of childhood patients who received treatment with ELT for persistent thrombocytopenia after alloHSCT between May 2016 and August 2019. We evaluated the safety and efficacy of ELT in 18 childhood patients with PIT or SFPR after alloHSCT. Eltrombopag (50 mg/d) treatment was started in all patients, above 6 years of age and 20 kg weight, who had thrombocytopenia despite neutrophil engraftment on the 30th day of HSCT. Our objective was to decrease the need for platelet transfusion and have a platelet count of more than 50 000/µL. The overall response rate was 77.7%. The median time to achieve a platelet level above 30 000/µL and 50 000/µL was 21 and 44 days, respectively. In four patients, platelet count never reached 30 000/mm3. In two patients, the treatment was discontinued due to grade 3 hepatotoxicity. Our study supports the efficacy and relative safety of ELT use for the treatment of PIT and SFPR seen after alloHSCT in children.
- 1 August 2020
- Published by Galenos Yayinevi in Güncel Pediatri
- Vol. 18 (2) , 237-250
Effects of Genetic Modifiers on Clinics of Beta Thalassemia Major and Intermedia
- 1 August 2020
- Published by Galenos Yayinevi in Güncel Pediatri
- Vol. 18 (2) , 237-250
Effects of Genetic Modifiers on Clinics of Beta Thalassemia Major and Intermedia
- Open Access
- 1 January 2018
- Published by Termedia Sp. z.o.o. in Contemporary Oncology
- Vol. 22 (2) , 105-107
Non-typhoidal Salmonella bacteraemia in paediatric leukaemia patients
Non-typhoidal Salmonella (NTS) is an important pathogen that causes gastroenteritis, bacteraemia, and focal infections. Herein, we present our experience with bloodstream infections caused by Salmonella in paediatric leukaemia patients, which has been reported for the first time in both Europe...
- 1 January 2018
- Published by Termedia Sp. z.o.o. in Contemporary Oncology
- Vol. 22 (2) , 105-107
Open AccessNon-typhoidal Salmonella bacteraemia in paediatric leukaemia patients
Non-typhoidal Salmonella (NTS) is an important pathogen that causes gastroenteritis, bacteraemia, and focal infections. Herein, we present our experience with bloodstream infections caused by Salmonella in paediatric leukaemia patients, which has been reported for the first time in both Europe...
- Open Access
- 29 October 2015
- Published by Journal of Infection in Developing Countries in The Journal of Infection in Developing Countries
- Vol. 9 (10) , 1172-1176
Secondary hemophagocytic lymphohistiocytosis in children with brucellosis: report of three cases
Brucellosis is a systemic zoonotic infectious disease that may cause fever, fatigue, sweating, arthritis, hepatosplenomegaly, cytopenia, and lymphadenopathy. It continues to be an important health problem worldwide. Hemophagocytic lymphohistiocytosis (HLH) is characterized by fever, hepatosplenomegaly, cytopenias, high serum levels of ferritin and triglycerides, low serum fibrinogen levels, and hemophagocytosis in bone marrow, lymph nodes, spleen, or liver. Hemophagocytic lymphohistiocytosis associated with brucellosis is a very rare condition in the pediatric age group. Here, three pediatric cases of secondary HLH associated with brucellosis are reported. Hemophagocytic lymphohistiocytosis should be considered in patients with brucellosis having cytopenias. Hemophagocytosis in brucellosis seems to be cured with appropriate antibiotics and intravenous immunoglobulin.
- 29 October 2015
- Published by Journal of Infection in Developing Countries in The Journal of Infection in Developing Countries
- Vol. 9 (10) , 1172-1176
Open AccessSecondary hemophagocytic lymphohistiocytosis in children with brucellosis: report of three cases
Brucellosis is a systemic zoonotic infectious disease that may cause fever, fatigue, sweating, arthritis, hepatosplenomegaly, cytopenia, and lymphadenopathy. It continues to be an important health problem worldwide. Hemophagocytic lymphohistiocytosis (HLH) is characterized by fever, hepatosplenomegaly, cytopenias, high serum levels of ferritin and triglycerides, low serum fibrinogen levels, and hemophagocytosis in bone marrow, lymph nodes, spleen, or liver. Hemophagocytic lymphohistiocytosis associated with brucellosis is a very rare condition in the pediatric age group. Here, three pediatric cases of secondary HLH associated with brucellosis are reported. Hemophagocytic lymphohistiocytosis should be considered in patients with brucellosis having cytopenias. Hemophagocytosis in brucellosis seems to be cured with appropriate antibiotics and intravenous immunoglobulin.